Brandywine Managers’s Denali Therapeutics DNLI Stock Holding History

Brandywine Managers’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,601	Closed	-$206K	–	41
2023 Q4	$206K	Buy	+9,601	New	+$190K	0.23%	40
2023 Q3	–	Sell	-9,601	Closed	-$283K	–	42
2023 Q2	$283K	Hold	9,601	–	–	0.19%	43
2023 Q1	$221K	Hold	9,601	–	–	0.16%	46
2022 Q4	$267K	Hold	9,601	–	–	0.93%	32
2022 Q3	$295K	Hold	9,601	–	–	0.97%	31
2022 Q2	$283K	Hold	9,601	–	–	0.69%	33
2022 Q1	$309K	Hold	9,601	–	–	0.53%	37
2021 Q4	$428K	Buy	9,601 +1,050	+12%	+$49.7K	0.49%	37
2021 Q3	$431K	Hold	8,551	–	–	0.45%	38
2021 Q2	$671K	Buy	+8,551	New	+$529K	0.77%	29

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Brandywine Managers's DNLI Position: Q1 2024 in Review

Brandywine Managers sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 9,601 shares — an estimated $206K sold.

Brandywine Managers first reported a position in DNLI in Q2 2021 and held it in 10 quarters. The position peaked at $671K in Q2 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

Brandywine Managers reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
Brandywine Managers sold 9,601 Denali Therapeutics shares in Q1 2024, an estimated $206K.
Brandywine Managers first reported a position in Denali Therapeutics in Q2 2021 and held it in 10 quarters.
Brandywine Managers's Denali Therapeutics position peaked at $671K in Q2 2021.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Brandywine Managers's 13F filing for Q1 2024, filed 15 May 2024.